Bicara Therapeutics (BCAX) Shares Outstanding (Diluted Average) (2023 - 2026)

Bicara Therapeutics has reported Shares Outstanding (Diluted Average) for 4 years, with the latest figure at $60.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 11.5% year-over-year to $60.7 million; the trailing twelve-month figure through Mar 2026 stood at $60.7 million (up 11.5% YoY), and the FY2025 full-year result was $54.7 billion, up 225.35% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $60.7 million, down from $54.7 billion in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $54.7 billion in Q4 2025, with the low at $597586.0 in Q3 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $6.6 billion across 4 years, with a median of $54.5 million in 2025.
• Annual changes were most pronounced in 2025 — Shares Outstanding (Diluted Average) soared 8147.39% — and 2026, when it climbed 11.5%.
• Bicara Therapeutics' Shares Outstanding (Diluted Average) stood at $580.1 million in 2023, then surged by 2796.96% to $16.8 billion in 2024, then jumped by 225.35% to $54.7 billion in 2025, then plunged by 99.89% to $60.7 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $60.7 million (Q1 2026), $54.7 billion (Q4 2025), and $54.5 million (Q3 2025), per Business Quant data.